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Coronary artery calcification is an index of the severity of
atherosclerotic vascular disease, and may predict future
adverse cardiovascular events in uremic patients undergoing
hemodialysis (HD). HD patients are exposed to oxidative
stress, and show high plasma levels of advanced glycation
end products (AGEs). The association between oxidative
stress, AGEs, established cardiovascular risk factors, and
coronary artery calcification score (CACS) was studied in 225
HD patients (123 male, 102 female patients). CACS was
measured by using multi-detector row computed
tomography. Age, systolic blood pressure, calcium,
calciumphosphate, malondialdehyde, lipid peroxides, and
pentosidine were significantly and positively correlated with
CACS. Duration on HD tended to be positively correlated with
CACS. From the independent variables included in the
forward stepwise multiple linear regression analysis, only
age, systolic blood pressure, lipid peroxides, calcium, and
pentosidine were independently associated with CACS. The
odds ratios for past history of coronary artery disease and the
presence of diabetes mellitus for high CACS (X100) were
6.25 (95% confidence interval; 1.83–21.4) and 2.03 (95%
confidence interval; 1.02–4.05), respectively. The plasma
pentosidine was significantly and positively correlated with
indoxyl sulfate. In conclusion, in addition to such traditional
cardiovascular risk factors as past history, diabetes mellitus,
aging, systolic blood pressure and calcium overload,
oxidative stress (lipid peroxides), and AGE (pentosidine) are
associated with extensive coronary artery calcification in HD
patients. Lipid peroxidation and glycoxidation may be
involved in the pathogenesis of coronary artery calcification.
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Cardiovascular mortality is substantially elevated in dialysis
patients and the risk for cardiovascular mortality is
approximately 10 times (range 2.5–17.0) higher than that of
general population.1 In patients treated by hemodialysis
(HD) or peritoneal dialysis, the prevalence of coronary artery
disease is approximately 40%, and the risk for death from a
cardiovascular event is 20-fold greater in these patients than
in general population.2 Cardiovascular risk evaluation is
important in the potential transplant recipients before kidney
transplantation, because cardiovascular disease is the major
cause of death in this population.3 Coronary plaque is
significantly more prevalent in dialysis patients than in non-
dialysis patients.4–7 Thus, early detection of coronary artery
disease in dialysis patients could be of major clinical
importance. Coronary artery calcification is regarded as an
index of the severity of atherosclerotic vascular disease, and
may predict future adverse cardiovascular events, especially
in patients on dialysis therapy.8–16
Oxidative stress, defined as a perturbation in the pro-
oxidant and antioxidant balance, has been strongly implicated
in both atherosclerosis and myocardial dysfunction in diverse
human and animal studies.17 Patients on chronic HD are
exposed to oxidative stress and inflammation.15 In the presence
of oxidative stress, oxidation of carbohydrates and lipids may
lead to the formation of reactive carbonyl compounds,
resulting in the formation of advanced glycoxidation and
lipoxidation end products.15,16 Lipid peroxidation is enhanced
in the plasma and erythrocytes in uremic patients.18,19
Formation of advanced glycation end products (AGEs) is
initiated by the reaction of reducing sugars with free amino
groups of proteins or amino acids. In this reaction, a labile
Schiff ’s base is produced, followed by its rearrangement into
Amadori products and, finally, after further reaction
cascades, into a wide range of AGEs.20 Accumulation of
AGEs in tissues contributes to normal aging processes,21 and
is accelerated by enhanced production (e.g. diabetes mellitus)
and also by decreased renal removal of glycoxidation
products and AGEs precursors (e.g. end-stage renal dis-
ease).22 In end-stage renal disease, markedly elevated serum
levels of AGEs have been established,23,24 with no difference
between patients with and without diabetes,25 indicating a
pivotal role of the kidney in AGEs metabolism.
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Factors correlating with coronary artery calcification have
not been adequately investigated in HD patients. Thus, we
examined association between oxidative stress, AGEs, estab-
lished cardiovascular risk factors, inflammation, calcium,
phosphate, and coronary artery calcification score (CACS) in
HD patients.
RESULTS
Table 1 shows the clinical characteristics of 225 HD patients
(men: 54.7%; women: 45.3%) stratified by CACS. Average
CACS was 1323 ranging from 0 to 15481. The patients were
classified into five groups according to the severity of CACS:
no CACS (0), n¼ 22 (9.8%); minimal CACS (1–100), n¼ 47
(20.9%); mild CACS (101–400), n¼ 36 (16.0%); moderate
CACS (401–1000), n¼ 38 (16.9%); and severe CACS (41000),
n¼ 82 (36.4%). Age, systolic blood pressure, creatinine,
malondialdehyde, and lipid peroxides were significantly
different between the five groups classified by CACS.
Table 2 shows the correlation coefficients of variables
versus CACS. Age, systolic blood pressure, calcium, cal-
cium phosphate, malondialdehyde, lipid peroxides, and
pentosidine were significantly and positively correlated with
CACS. Especially, lipid peroxides and malondialdehyde as
markers of oxidative stress showed strong positive correla-
tions with CACS.
Figure 1 shows correlation between CACS and duration
on HD. Duration on HD tended to be positively correlated
with CACS (r¼ 0.12, P¼ 0.06). Especially, those patients
with age less than 60 years showed significantly positive
correlation between duration on HD and CACS (r¼ 0.33,
Po0.001), although older patients with age above 60 years
did not show any significant correlation between duration on
HD and CACS (r¼0.011, not significant). Figure 2 shows
correlation between CACS with lipid peroxides. Lipid
peroxides was significantly and positively correlated with
CACS (r¼ 0.31, Po0.0001). Figure 3 shows correlation
Table 1 | Clinical characteristics of HD patients stratified by CACS
CACS
Variables Total 0 1–100 101–400 401–1000 41000 P-value
Subjects (n) 225 22 47 36 38 82
Male/female 123/102 7/15 26/21 22/14 19/19 49/33
Age (years) 60713 48712 53711 64712 63713 65711 o0.0001
Duration on hemodialysis (years) 8.978.2 8.979.2 6.576.0 7.878.2 10.877.9 10.078.9 0.09
Past history (n) 33 0 3 5 4 21
Family history (n) 21 3 8 3 2 5
Smoker (n) 38 3 10 6 8 11
Diabetes mellitus (n) 63 4 9 17 10 23
Hypertension (n) 116 12 22 17 20 45
Calcium medication (n) 186 20 40 29 31 66
Vitamin D medication (n) 141 16 30 20 25 50
Calcium antagonist medication (n) 88 8 16 16 10 38
HMG-CoA reductase inhibitor (n) 23 2 5 2 2 12
Nicotinic acid medication (n) 5 1 2 0 0 2
Systolic blood pressure (mm Hg) 143724 133724 135717 143720 149727 150725 o0.005
Diastolic blood pressure (mm Hg) 75714 73714 76713 73715 78713 75713 NS
Hematocrit (%) 32.9719.4 31.873.1 31.873.2 32.173.5 31.573.2 31.273.0 NS
Total protein (g/dl) 7.070.5 7.170.6 7.170.5 7.070.4 6.970.5 7.070.5 NS
Albumin (g/dl) 4.170.4 4.270.5 4.270.4 4.070.4 4.170.3 4.170.3 0.09
Creatinine (mg/dl) 12.772.9 13.473.0 13.972.5 11.972.7 12.673.2 12.272.8 o0.01
Blood urea nitrogen (mg/dl) 74.1715.8 77.6716.6 77.8716.8 74.6715.8 71.0715.8 72.3714.8 NS
Uric acid (mg/dl) 8.371.3 8.771.4 8.471.1 8.271.3 8.371.2 8.171.4 NS
Total cholesterol (mg/dl) 169736 168740 170739 160737 175732 169734 NS
LDL-cholesterol (mg/dl) 99729 96737 98732 93727 106731 99726 NS
HDL-cholesterol (mg/dl) 44713 45.4715.9 43.3712.4 42.1713.5 46.1711.6 44.0712.7 NS
Triglyceride (mg/dl) 1357104 133769 145784 124769 114750 1447146 NS
Calcium (mg/dl) 4.2670.46 4.3170.43 4.1670.41 4.1570.46 4.2770.46 4.3470.49 NS
Phospate (mg/dl) 5.9271.17 6.1370.90 5.7971.02 5.7671.12 6.1071.17 5.9471.33 NS
Calciumphospate (mg2/dl2) 25.376.0 26.675.4 24.074.5 24.075.9 26.276.3 25.876.6 NS
CRP (mg/dl) 0.2470.60 0.1570.25 0.1770.34 0.3671.04 0.1670.34 0.2970.62 0.07
Homocysteine (mmol/l) 36.5722.4 28.6710.2 39.9721.7 33.5720.2 41.0731.8 35.9720.6 NS
Malondialdehyde (nmol/ml) 1.6870.28 1.5270.24 1.6270.25 1.7370.22 1.6370.25 1.7670.32 o0.005
Lipid peroxides (nmol/ml) 1.2470.89 0.9470.20 1.3370.86 1.1170.62 1.2570.68 1.3371.15 o0.0001
Ne-(carboxymethyl)lysine (mg/ml) 9.8072.06 9.3172.19 9.9871.96 9.8571.92 9.7672.57 9.8271.90 NS
Pentosidine (mg/ml) 0.4470.15 0.3970.14 0.4370.13 0.4570.16 0.4270.11 0.4870.17 0.06
Indoxyl sulfate (mg/ml) 35.2714.7 29.8718.0 34.2713.4 35.9714.1 35.2712.6 37.1715.6 NS
Kt/V 1.3470.24 1.4070.22 1.3170.28 1.2970.26 1.4170.21 1.3470.20 NS
CACS 132372110 070 34730 220788 6767179 3200.472560 o0.0001
CACS, coronary artery calcification score; CRP, C-reactive protein; HD, hemodialysis; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; HDL-cholesterol, high-density
lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; Kt/V, hemodialysis dose; K, urea clearance; t, dialysis time; V, body water volume; NS, not
significant.
Values are expressed as mean7s.d.
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between CACS and pentosidine. Pentosidine was significantly
and positively correlated with CACS (r¼ 0.17, Po0.05).
Forward stepwise multiple linear regression analysis was
performed using CACS as the dependent variable, and age,
duration on HD, systolic blood pressure, diastolic blood
pressure, hemotocrit, total protein, albumin, creatinine,
blood urea nitrogen, uric acid, total cholesterol, low-density
lipoprotein (LDL)-cholesterol, high-density lipoprotein
(HDL)-cholesterol, triglyceride, calcium, phosphate, cal-
cium phosphate, C-reactive protein, homocysteine, mal-
ondialdehyde, lipid peroxides, Ne-(carboxymethyl)lysine,
pentosidine, and indoxyl sulfate as independent variables.
From many independent variables included in the analysis,
age, systolic blood pressure, lipid peroxides, calcium, and
pentosidine were independently associated with CACS
(Table 3).
Table 4 shows odds ratios for high CACS (X100) in the
past history and family history of angina pectoris and/or
myocardial infarction, smoking, diabetes mellitus and
hypertension as underlying disease, and medication (calcium
carbonate, vitamin D analogues, calcium channel blockers,
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors, and nicotinic acid). The odds ratios for
high CACS in the past history was 6.25 (95% confidence
interval: 1.83–21.4, Po0.005), and CACS was significantly
increased in HD patients with the past history as compared
without it (289373065 vs 94271762, Po0.0001, respec-
tively). The odds ratios for high CACS in diabetes mellitus
was 2.03 (95% confidence interval: 1.02–4.05, Po0.05),
although there was no significant difference in CACS between
the presence and absence of diabetes mellitus (123371646 vs
135872269, not significant, respectively). There were no
significant associations between the medication and CACS.
Table 2 | Correlation coefficients between variables and CACS
CACS
Variables Correlation coefficient (r) P-value
Age 0.21 o0.005
Duration on hemodialysis 0.12 0.06
Systolic blood pressure 0.22 o0.005
Diastolic blood pressure 0.07 NS
Hematocrit 0.06 NS
Total protein 0.09 NS
Albumin 0.05 NS
Creatinine 0.08 NS
Blood urea nitrogen 0.03 NS
Total cholesterol 0.01 NS
LDL-cholesterol 0.02 NS
HDL-cholesterol 0.04 NS
Triglyceride 0.11 NS
Uric acid 0.10 NS
Calcium 0.15 o0.05
Phosphate 0.10 NS
Calciumphosphate 0.16 o0.05
CRP 0.01 NS
Homocysteine 0.02 NS
Malondialdehyde 0.22 o0.005
Lipid peroxides 0.31 o0.0001
Ne-(carboxymethyl)lysine 0.02 NS
Pentosidine 0.17 o0.05
Indoxyl sulfate 0.03 NS
CACS, coronary artery calcification score; CRP, C-reactive protein; HDL-cholesterol,
high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein
cholesterol; NS, not significant.
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Figure 1 | Correlation between CACS and duration on HD in HD
patients.
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Figure 2 | Correlation between CACS and plasma lipid peroxides
in HD patients.
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Figure 3 | Correlation between CACS and plasma pentosidine in
HD patients.
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DISCUSSION
In the present study, we demonstrated in 225 HD patients
that oxidative stress (lipid peroxides) and AGE (pentosidine)
in addition to age, systolic blood pressure, and calcium were
independently associated with CACS.
Age has been reported to be independently associated with
CACS in 79 HD patients.8 A stepwise multiple regression
analysis confirmed the importance of age and hypertension,
but did not show any correlation between calcium,
phosphate, parathyroid hormone, and CACS in 49 patients
on HD.9 Calcification was more prominent in older age, male
gender, non-black race, diabetes, longer dialysis duration,
and higher serum concentrations of calcium and phosphate
in 205 HD patients.10 Coronary artery calcification is
common and progressive in young adults with end-stage
renal disease in 39 patients on HD or peritoneal dialysis.11
On the other hand, age was not independently associated
with CACS, although CACS was positively and significantly
correlated with age in 53 HD patients.12 Dialysis patients
with or without progression of coronary artery disease did
not differ in age, duration on dialysis treatment, number of
cardiovascular risk factors, and plasma concentration of
lipids or fibrinogen in 26 patients on HD or peritoneal
dialysis.13 In the present study, sample size was large (225 HD
patients) as compared with these previous reports, and CACS
was positively and significantly correlated with age. Further-
more, age was independently associated with CACS. Thus,
our results are consistent with many previous studies, in
which CACS is accelerated by aging.
Systolic blood pressure has been reported to be positively
associated with CACS in asymptomatic adults.26 In HD
patients, systolic blood pressure has been reported to be
Table 3 | Stepwise multiple linear regression analysis by forward selection procedure for CACS as a dependent variable
Unstandardized coefficients Standard coefficients
Independent variables
Unstandardized
regression coefficients s.e
Standardized regression
coefficients F-value P-value
Age (years) 37.7 10.92 0.235 11.90 o0.005
Systolic blood pressure 16.3 6.01 0.184 7.34 o0.01
Lipid peroxides 478.1 181.471 0.173 6.94 o0.01
Calcium 756.4 302.020 0.169 6.27 o0.05
Pentosidine 2070.9 933.59 0.151 4.92 o0.05
CACS, coronary artery calcification score.
Variables used for analysis were as follows: age, duration on hemodialysis, systolic blood pressure, diastolic blood pressure, hematocrit, total protein, albumin, creatinine,
blood urea nitrogen, uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, calcium, phosphate, calcium phosphate, C-reactive protein, homocysteine,
malondialdehyde, lipid peroxide, Ne-(carboxymethyl)lysine, pentosidine, and indoxyl sulfate.The F-value for the inclusion and exclusion of variables was set at 4.0 at each step.
Multiple r=0.451, multiple R2=0.204, adjusted R2=0.182, analysis of variance F-ratio=9.459, Po0.0001.
Table 4 | OR and 95% CI for high CACS (X100)
High CACS X100 OR (95% CI) P-value
Past history
Angina pectoris and/or myocardial infarction () 1.0 (Reference) o0.005
(+) 6.25 (1.83–21.4)
Family history
Angina pectoris and/or myocardial infarction () 1.0 (Reference) 0.05
(+) 0.40 (0.16–1.01)
Social history
Smoking () 1.0 (Reference) NS
(+) 1.03 (0.49–2.18)
Underlying diseases
Diabetes mellitus () 1.0 (Reference) o0.05
(+) 2.03 (1.02–4.05)
Hypertension () 1.0 (Reference) 0.08
(+) 1.72 (0.94–3.14)
Chronic use of medication
Calcium carbonate (n) () 1.0 (Reference) NS
(+) 0.63 (0.28–1.41)
Vitamin D analogues (n) () 1.0 (Reference) NS
(+) 0.86 (0.48–1.55)
Calcium channel blockers (n) () 1.0 (Reference) NS
(+) 1.35 (0.75–2.45)
HMG-CoA reductase inhibitors (n) () 1.0 (Reference) NS
(+) 0.94 (0.37–2.43)
Nicotinic acid (n) () 1.0 (Reference) NS
(+) 0.29 (0.05–1.75)
CACS, coronary artery calcification score; CI, confidence interval; OR, odds ratio; NS, not significant.
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positively associated with abdominal aortic calcification and
aortic arch calcification.27,28 Thus, some reports suggest that
systolic blood pressure is correlated with vascular calcifica-
tion. However, association between CACS and systolic blood
pressure has not adequately been studied in HD patients. Our
results demonstrated that systolic blood pressure is indepen-
dently and significantly correlated with CACS.
A recent study reported that CACS was correlated with
phosphate and calcium phosphate in 79 HD patients,14 and
concluded by using stepwise linear regression analysis that
CACS was associated with age, duration on HD, phosphate,
and carotid plaque score. Another study reported that CACS
was correlated with age, calcium, calcium phosphate, and
intact parathyroid hormone in 30 HD patients.29 In the
present study, calcium and calcium phosphate were
positively correlated with CACS in 225 HD patients. Further,
calcium was independently associated with CACS.
Uremic patients on chronic HD are exposed to oxidative
stress.17 Plasma levels of malondialdehyde and lipid peroxides
are used as biomarkers of oxidative stress. Malondialdehyde
is the breakdown product of the major reaction that leads to
the definitive oxidation of polyunsaturated fatty acids, such
as linoleic and linolenic acids, and serves as a reliable marker
of lipid peroxidation. The serum concentration of mal-
ondialdehyde was elevated in end-stage renal disease patients
with a documented history of cardiovascular disease,
including myocardial infarction, angina pectoris, stroke,
transient cerebral ischemia, and peripheral vascular disease.30
However, any evidence regarding the association between
oxidative stress markers and coronary artery disease diag-
nosed by imaging techniques has not been demonstrated. We
demonstrated that lipid peroxides and malondialdehyde were
positively and significantly correlated with CACS. Further-
more, lipid peroxides were independently associated with
CACS by using the forward stepwise multiple linear
regression analysis. Malondialdehyde (F¼ 3.24) showed
strong correlation next to pentosidine (F¼ 4.92). Oxidative
stress, especially lipid peroxidation, is associated with
extensive CACS. An in vitro experiment demonstrated that
increased intracellular oxidative stress enhanced osteoblastic
differentiation of vascular cells, based on alkaline phospha-
tase activity and mineralization.31 Thus, enhanced oxidative
stress modulates differentiation of vascular cells, which may
explain enhanced vascular calcification in HD patients.
Accumulation of AGEs in arteriosclerotic lesions has been
suggested to play an important role in the development and
progression of arteriosclerosis.32 Plasma level of pentosidine
is correlated with aorta calcification index in HD patients.32
However, the association of pentosidine with CACS has not
yet been investigated. In the present study, pentosidine, an
AGE, was positively and significantly correlated, and
independently associated with CACS in HD patients. The
formation of pentosidine is accelerated by oxidative stress,33
and therefore, pentosidine is a glycoxidation product. Thus,
oxidative stress may also account for pentosidine as well as
lipid peroxides as risk factors for extensive CACS. In the
present study, the plasma level of pentosidine was positively
and significantly correlated with indoxyl sulfate in 225 HD
patients (Figure 4). The accumulation of indoxyl sulfate in
uremic plasma may enhance oxidative stress in HD patients.
Dyslipidemia (low HDL-cholesterol, elevated triglycerides,
elevated LDL-cholesterol, and elevated total cholesterol) has
been reported to be an important factor in the cardiovascular
calcification process.34–36 However, we could not confirm any
significant associations between the lipid profiles and CACS
in 225 HD patients. Reduction of LDL-cholesterol by
treatment with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) ameliorated coronary artery
calcification in subjects with normal renal function.37
Unfortunately, the effect of lowering the LDL-cholesterol
level on CACS has not been studied in HD patients.
In conclusion, in addition to the traditional risk factors
for cardiovascular disease such as past history, diabetes
mellitus, aging, systolic blood pressure and calcium, lipid
peroxides, and pentosidine are associated with extensive
coronary artery calcification in HD patients. Lipid oxidation
and glycoxidation may play an important role in the
pathogenesis of coronary artery calcification.
MATERIALS AND METHODS
Subjects
This study included 225 HD patients from a single dialysis unit
(Meiyo Clinic, Toyohashi, Aichi, Japan), who agreed to enter the
study. No specific selection criteria were used in order to obtain a
representative population of HD patients. In this cross-sectional
study, all patients had been treated on HD for 8.878.2 years ranging
from 3 months to 33.6 years. Table 1 shows the clinical
characteristics and the biochemical parameters of the patients. The
HD patients were dialyzed for 4 h three times a week.
Laboratory assessment
All blood samples were obtained just before dialysis procedure, and
then centrifuged at 3 000 g for 10 min at 41C. After separation of
plasma, samples were immediately frozen at 801C until analysis.
The following biochemical parameters were determined: hematocrit,
total protein, albumin, creatinine, blood urea nitrogen, uric acid,
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Figure 4 | Correlation between plasma levels of indoxyl sulfate
and pentosidine in HD patients.
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total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride,
calcium, phosphate, highly sensitive C-reactive protein, homocys-
teine, malondialdehyde, lipid peroxides, Ne-(carboxymethyl)lysine,
pentosidine, and indoxyl sulfate. As markers of oxidative stress, lipid
peroxidases and malondialdehyde were measured, and Ne-(carboxy-
methyl)lysine and pentosidine were measured as markers of AGEs.
The plasma level of highly sensitive C-reactive protein was
measured using Behring Nephelometer II (BNIITM) (Dade Behring,
Tokyo, Japan). The plasma level of lipid peroxides was measured by
using the hemoglobin–methylene blue method.38 The plasma level of
malondialdehyde was measured as malondialdehyde-thiobarbituric
acid reactive substances by using the Yagi method.39 The plasma
levels of Ne-(carboxymethyl)lysine and pentosidine were measured
by using the enzyme-linked immunosorbent assay method with
Benchmark Microplate Reader (Bio-Rad Laboratories Inc., Hercules,
CA, USA). The plasma level of homocysteine40 and the serum level
of indoxyl sulfate41 were measured by high-performance liquid
chromatography method with fluorescence detection.
Coronary artery calcification score
CACS was measured by using multi-16-detector row computed
tomography (Aquilion 16, Toshiba Medical Systems Corporation,
Tokyo, Japan). All scans were interpreted by three radiologists, to
minimize the inter-observer variability of results. Threshold calcium
determination was set using a density of at least 110 Hounsfield
units (HU), with a minimal area of three pixels. Slices of 1.0-mm
thickness were acquired under the following conditions: 400 mA of
the tube current at 120 kV. The entire heart was covered in a single
breast-hold (20–30 s). CACS was evaluated according to the method
of Agatston et al.42 (area co-factor; 1: 110–199 HU; 2: 200–299 HU;
3: 300–399 HU; 4: 4400 HU). Data obtained during the diastolic
phase of the heart cycle were used for image reconstruction. CACS
was calculated by summing the calcification scores in right coronary
artery, left artery descending branch, circumflex branch, and left
main trunk.
Statistical analysis
Statistical analysis of data was performed by using STATA version 8
statistical software (Stata Corporation LP, College Station, TX, USA)
and Stat View version 5.0 statistical software (SAS Corporation,
Cary, NC, USA). All variables are expressed as mean7s.d.
Comparison between more than three groups was performed using
one-way analysis of variance. In search for correlations between
variables, Pearson’s correlation test was used. The differences in the
numbers of subjects by CACS were analyzed by w2 independent test,
odds ratioss, and confidence intervals. To assess the influence of
tested parameters, forward stepwise multiple linear regression
analysis was used. The F-value was set at 4.0 at each step. P-values
less than 0.05 were considered to be statistically significant. Non-
paired t-test was applied for the comparison between two groups.
REFERENCES
1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular
disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112–S119.
2. Schalkwijk CG, Posthuma N, ten Brink HJ et al. Induction of 1,
2-dicarbonyl compounds, intermediates in the formation of advanced
glycation endproducts, during heat-sterilization of glucose-based
peritoneal dialysis fluids. Perit Dial Int 1999; 19: 325–333.
3. Fishbane S. Cardiovascular risk evaluation before kidney transplantation.
J Am Soc Nephrol 2005; 16: 843–845.
4. Clyne N, Lins LE, Pehrsson SK. Occurrence and significance of heart
disease in uraemia. An autopsy study. Scand J Urol Nephrol 1986; 20:
307–311.
5. Ansari A, Kaupke CJ, Vaziri ND et al. Cardiac pathology in patients with
end-stage renal disease maintained on hemodialysis. Int J Artif Organs
1993; 16: 31–36.
6. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease:
Insights from coronary angiography. Kidney Int 1984; 25: 653–659.
7. Ikram H, Lynn KL, Bailey RR et al. Cardiovascular changes in chronic
hemodialysis patients. Kidney Int 1983; 24: 371–376.
8. Yildiz A, Tepe S, Oflaz H et al. Carotid atherosclerosis is a predictor of
coronary calcification in chronic haemodialysis patients. Nephrol Dial
Transplant 2004; 19: 885–891.
9. Braun J, Oldendorf M, Moshage W et al. Electron beam computed
tomography in the evaluation of cardiac calcification in chronic dialysis
patients. Am J Kidney Dis 1996; 27: 394–401.
10. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult
hemodialysis patients. A link between end-stage renal disease and
cardiovascular disease? J Am Coll Cardiol 2002; 39: 695–701.
11. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in
young adults with end-stage renal disease who are undergoing dialysis.
N Engl J Med 2000; 342: 1478–1483.
12. Nitta K, Akiba T, Suzuki K et al. Assessment of coronary artery calcification
in hemodialysis patients using multi-detector spiral CT scan. Hypertens
Res 2004; 27: 527–533.
13. Gradaus F, Ivens K, Peters AJ et al. Angiographic progression of coronary
artery disease in patients with end stage renal disease. Nephrol Dial
Transplant 2001; 16: 1198–1202.
14. Yildiz A, Tepe S, Oflaz H et al. Carotid atherosclerosis is a predictor of
coronary calcification in chronic haemodialysis patients. Nephrol Dial
Transplant 2004; 19: 885–891.
15. Kaul N, Siveski-Iliskovic N, Hill M et al. Free radicals and the heart.
J Pharmacol Toxicol Methods 1993; 30: 55–67.
16. Schwedler S, Schinzel R, Vaith P et al. Inflammation and advanced
glycation end products in uremia: simple coexistence, potentiation or
causal relationship? Kidney Int 2001; 59(Suppl 78): S32–S36.
17. Miyata T, Ueda Y, Yamada Y et al. Accumulation of carbonyls
accelerates the formation of pentosidine, an advanced glycation
end product: carbonyl stress in uremia. J Am Soc Nephrol 1998; 9:
2349–2356.
18. Himmelfarb J, Lazarus JM, Hakim R. Reactive oxygen species production
by monocytes and polymorphonuclear leukocytes during dialysis. Am J
Kidney Dis 1991; 17: 271–276.
19. Luciak M, Trznadel K. Free oxygen species metabolism during
haemodialysis with different membranes. Nephrol Dial Transplant
1991; 6(Suppl 3): 66–70.
20. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu
Rev Med 1995; 46: 223–234.
21. Odetti P, Pronzato MA, Noberasco G et al. Relationships between
glycation and oxidation related fluorescence in rat collagen during aging
– an in vivo and in vitro study. Lab Invest 1994; 70: 61–67.
22. Monnier VM, Sell DR, Miyata S et al. Advanced Maillard reaction products
as markers for tissue damage in diabetes and uremia: relevance to
diabetic nephropathy. Acta Diabetol 1992; 29: 130–135.
23. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in
diabetic uremia and treatment of renal failure. Lancet 1994; 343:
1519–1522.
24. Dawnay A, Millar DJ. The pathogenesis and consequences of AGE
formation in uraemia and its treatment. Cell Mol Biol 1998; 44: 1081–1094.
25. Weiss MF, Erhard P, Kader-Attia FA et al. Mechanisms for the formation of
glycoxidation products in end-stage renal disease. Kidney Int 2000; 57:
2571–2585.
26. Bielak LF, Turner ST, Franklin SS et al. Age-dependent associations
between blood pressure and coronary artery calcification in asympto-
matic adults. J Hypertens 2004; 22: 719–725.
27. Kimura K, Saika Y, Otani H et al. Factors associated with calcification of the
abdominal aorta in hemodialysis patients. Kidney Int Suppl 1999; 71:
S238–S241.
28. Fabbian F, Catalano C, Orlandi V et al. Evaluation of aortic arch
calcification in hemodialysis patients. J Nephrol 2005; 18:
289–293.
29. Splendiani G, Morosetti M, Manni M et al. Cardiac calcium evaluation in
hemodialysis patients with multisection spiral computed tomography. Int
J Artif Organs 2004; 27: 759–765.
30. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent
cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078–1083.
31. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates
osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med
2001; 31: 509–519.
Kidney International (2006) 70, 218–224 223
K Taki et al.: Coronary artery calcification in hemodialysis patients o r i g i n a l a r t i c l e
32. Kitauchi T, Yoshida K, Yoneda T et al. Association between pentosidine
and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol
2004; 8: 48–53.
33. Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative
stress in the formation of advanced glycation end products in
patients with end-stage renal failure. Kidney Int 1997; 51:
1170–1181.
34. McCullough PA, Soman S. Cardiovascular calcification in patients with
chronic renal failure: are we on target with this risk factor? Kidney Int
Suppl 2004; 90: S18–S24.
35. McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of
coronary vascular calcification in patients with chronic kidney disease
and end-stage renal disease: a systematic review. J Nephrol 2004; 17:
205–215.
36. McCullough PA. Effect of lipid modification on progression
of coronary calcification. J Am Soc Nephrol 2005; 16(Suppl 2):
S115–S119.
37. Achenbach S, Ropers D, Pohle K et al. Influence of lipid-lowering therapy
on the progression of coronary artery calcification: a prospective
evaluation. Circulation 2002; 106: 1077–1082.
38. Ohishi N, Ohkawa H, Miike A et al. A new assay method for lipid peroxides
using a methylene blue derivative. Biochem Int 1985; 10: 205–211.
39. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma.
Biochem Med 1976; 15: 212–216.
40. Vester B, Rasmussen K. High performance liquid chromatography
method for rapid and accurate determination of homocysteine in plasma
and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549–554.
41. Niwa T, Takeda N, Tatematsu A et al. Accumulation of indoxyl sulfate,
an inhibitor of drug-binding, in uremic serum as demonstrated by
internal-surface reversed-phase liquid chromatography. Clin Chem 1988;
34: 2264–2267.
42. Agatston AS, Janowitz WR, Hildner FJ et al. Quantification of coronary
artery calcium using ultrafast computed tomography. J Am Coll Cardiol
1990; 15: 827–832.
224 Kidney International (2006) 70, 218–224
o r i g i n a l a r t i c l e K Taki et al.: Coronary artery calcification in hemodialysis patients
